Close

Your source for biotech start-up, investor, and acquirer data.

CB Insights helps you track the world's most promising private companies, their investors, their acquirers and the industries they compete in to help you sell more.

Some of our smart, happy customers

nea logo

Explainer Video

A sample of our biotech data

Top Funded Biotech Companies

Top Funded Biotech Companies

Company Total Funding (M) Country Last Funding Round Last Funding Amount (M) Last Funding Investors
Moderna 699.73 United States Series E - II 50 Sign-up for CB Insights
Intrexon 509 United States Series F 150 Sign-up for CB Insights
Juno Therapeutics 310 United States Series B 134 Sign-up for CB Insights
Portola Pharmaceuticals 275.5 United States Series D - II 9 Sign-up for CB Insights
Lajolla Pharmaceutical Company 195.97 United States Unattributed VC - V 66 Sign-up for CB Insights
Orchid Cellmark 195.55 United States Unattributed VC - V 14.04 Sign-up for CB Insights
Immatics Biotechnologies 190.41 Germany Series D - II 30 Sign-up for CB Insights
Vital Therapies 189.24 United States Series F - II 13.93 Sign-up for CB Insights
Accera 180.26 United States Corporate Minority - II 84.08 Sign-up for CB Insights
MannKind 175 United States Unattributed VC 175 Sign-up for CB Insights
Neurogen 171.57 United States PIPE - III 30.62 Sign-up for CB Insights
Inhibitex 171.32 United States Unattributed VC - IV 41.25 Sign-up for CB Insights
Cerenis Therapeutics 166.98 France Series C - II 13.86 Sign-up for CB Insights
FibroGen 162.52 United States Unattributed 6.02 Sign-up for CB Insights
Xencor 159.9 United States Series F 7.6 Sign-up for CB Insights
Trimeris 159.7 United States Unattributed VC - III 42.76 Sign-up for CB Insights
Theravance 159.33 United States Unattributed VC - II Sign-up for CB Insights
Zafgen 155.28 United States Debt - II 20 Sign-up for CB Insights
Cytokinetics 153.38 United States Unattributed VC - II 33 Sign-up for CB Insights
Zymogenetics 150 United States Series A 150 Sign-up for CB Insights
Amicus Therapeutics 146 United States Series D 60 Sign-up for CB Insights
XenoPort 145.57 United States Unattributed VC - IV 25 Sign-up for CB Insights
NantBioscience 145 United States Unattributed - II 45 Sign-up for CB Insights
Probiodrug 142.52 Germany Series D 19.42 Sign-up for CB Insights
Celator Pharmaceuticals 141.25 United States Series E - III 32.5 Sign-up for CB Insights

Below is just a sample of our biotech data.  Our data is easily exported to Excel, includes contact information, and can be segmented by industry, investor, financing round and more.

Rankings

Getting Started

©2015 CB Insights, All Rights Reserved